Lead Product(s): IC 800
Therapeutic Area: Ophthalmology Product Name: IC 800
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: IACTA PHARMACEUTICALS
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 07, 2021
Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 (acute) and IC805 and other DENKI drugs from Pharmaleads’ portfolio.